Plecanatide vs Mazdutide
Head-to-head comparison of Plecanatide (Plecanatide) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Mazdutide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Plecanatide | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | Approx. 1620 Da | ~5,000 Da |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | 5-7 days |
| Amino Acids | 16 | 37 |
| Typical Dose | 3 mg once daily | 1-6 mg weekly in obesity trials |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 28 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.